Fases iniciales de la psicosis
Actividades del grupo
Nuestro grupo de investigación desarrolla su actividad en el seno de la Sección de Enfermedades Autoinmunes del Servicio de Medicina Interna del Hospital Universitario Cruces. Acumulamos una dilatada experiencia clínica con pacientes afectos de lupus eritematoso sistémico (LES), síndrome antifosfolípido (SAF), esclerosis sistémica, síndrome de Sjögren y otras enfermedades autoinmunes. Somos una Unidad referente a nivel de la Comunidad Autónoma Vasca y desarrollamos, además, una intensa labor docente en este campo, contribuyendo a la formación específica de residentes de diversos hospitales españoles. Pertenecemos desde su constitución inicial al Grupo de Enfermedades Autoinmunes Sistémicas (GEAS) de la Sociedad Española de Medicina Interna (SEMI), con plena implicación tanto en la organización de programas formativos como en el desarrollo de proyectos de investigación multicéntricos, algunos de los cuales lideramos.
Como Unidad integrada en un Hospital Universitario de tercer nivel y con especial dedicación a la medicina de alta complejidad, entendemos que la investigación está íntimamente ligada a nuestra actividad clínica. De hecho, la enfocamos como una herramienta que permite responder preguntas relacionadas con la práctica diaria, con una traslación inmediata a la aplicación específica en nuestros pacientes.
En el capítulo investigador somos un grupo consolidado en el campo del LES y SAF. Nuestra investigación se centra fundamentalmente en aspectos clínicos y se basa en la recogida de datos observacionales. Dada la relativa rareza de estas enfermedades y su heterogeneidad, los estudios de cohortes prospectivas son una herramienta de investigación habitual en este campo, de hecho gran parte de la práctica clínica en estos pacientes está basada en estudios observacionales.
De nuestras contribuciones, queremos destacar los estudios que han identificado el SAF como un factor pronóstico adverso en pacientes con LES; los que han establecido los importantes efectos beneficiosos a largo plazo de los antipalúdicos en el lupus, incluyendo una mayor supervivencia; los que han definido el nivel de anticoagulación ideal en el SAF; o los que han contribuido a clarificar el papel de la vitamina D en el lupus.
En este momento tenemos en marcha líneas activas que se centran, entre otros aspectos, en el análisis del riesgo vascular y la arteriopatía subclínica en el LES y el SAF, en los determinantes genéticos de trombosis en pacientes con anticuerpos antifosfolípido o en el impacto de los corticoides en el pronóstico del lupus.
Mantenemos desde hace más de 10 años una colaboración estable con el grupo del Dr. Munther Khamashta, que dirige la Lupus Research Unit del St. Thomas' Hospital de Londres. Somos el único grupo español miembro de pleno derecho de SLICC (Systemic Lupus International Collaborating Clinics), grupo internacional de investigación en red que reúne a muchos de los principales investigadores internacionales en el campo del lupus. Formamos parte de los grupos de investigación de lupus, esclerodermia, vasculitis y terapias biológicas (BIOGEAS) del GEAS, y coordinamos el Registro Español de Lupus Eritematoso Sistémico (RELES), la primera cohorte de incepción a nivel nacional, que cuenta ya con más de 150 pacientes en seguimiento prospectivo. Igualmente, compartimos proyectos con el grupo liderado por la Profesora Ana Zubiaga, del Departamento de Genética, Antropología física y Fisiología animal de la UPV/EHU. Más recientemente, nos hemos sumado como colaboradores a los estudios genéticos multicéntricos en el campo de la esclerosis sistémica y las vasculitis que lidera el Dr. Javier Martín, del Instituto de Parasitología y Biomedicina López-Neyra de Granada.
Proyectos activos:
Factores pronósticos en el lupus eritematoso sistémico. Cohorte observacional lupus-cruces
Prevalencia y factores de riesgo de enfermedad cardiovascular en el lupus eritematoso sistémico
Estudio de las manifestaciones neuropsiquiátricas en el lupus
Variables asociadas al riesgo de neoplasias en el lupus eritematoso sistémico
Estudio de la frecuencia y factores predictores de toxicidad retiniana en pacientes con lupus en tratamiento con antipalúdicos
Definición y validación de escalas de actividad en lupus
Identificación de variables predictivas de trombosis en individuos con anticuerpos antifofolípido
Identificación de genes de susceptibilidad al síndrome antifosfolípido.
Prevalencia y factores de riesgo de enfermedad cardiovascular en el síndrome antifosfolípido
Factores pronósticos en el la esclerosis sistemica
Factores pronósticos en las miopatías inflamatorias
Factores pronósticos en las vasculitis sistémicas
Identificación de genes de susceptibilidad a la enfermedad de behçet
Eficacia y efectos adversos de los tratamientos biológicos en las enfermedades autoinmunes sistémicas
Estudio de los factores causales y pronósticos de preeclampsia
Estudio de las complicaciones y factores pronósticos en el embarazo de mujeres con enfermedades autoinmunes sistémicas
Coordinador/a del grupo
-
Rafael Segarra Echevarria
Coordinador de grupo
rafael.segarraechevarria@osakidetza.eus
CV resumen
Miembros del grupo
Publicaciones del grupo
Odagaki Y, Mikami M, Kinoshita M, Meana JJ, Callado LF, Garcia Sevilla JA, et al. Agonistic properties of a series of psychotropic drugs at 5-HT1A receptors in rat and human brain membranes determined by [35S]GTPgammaS binding assay. Pharmacol Rep. 2023. DOI:10.1007/s43440-023-00448-6.
Yanez Gomez F, Ramos Miguel A, Garcia Sevilla JA, Manzanares J, Femenia T. Regulation of Cortico-Thalamic JNK1/2 and ERK1/2 MAPKs and Apoptosis-Related Signaling Pathways in PDYN Gene-Deficient Mice Following Acute and Chronic Mild Stress. Int J Mol Sci. 2023; 24(3). DOI:10.3390/ijms24032303.
Nunez delMoral A, Bianchi PC, Brocos Mosquera I, Anesio A, Palombo P, Camarini R, et al. The Matricellular Protein Hevin Is Involved in Alcohol Use Disorder. Biomolecules. 2023; 13(2). DOI:10.3390/biom13020234.
Villa M, Martinez Vega M, Del Pozo A, Muneta Arrate I, Gomez Soria A, Muguruza C, et al. The Role of the Dopamine System in Post-Stroke Mood Disorders in Newborn Rats. Int J Mol Sci. 2023; 24(4). DOI:10.3390/ijms24043229.
Miquel Rio L, Sarries Serrano U, Pavia Collado R, Meana JJ, Bortolozzi A. The Role of alpha-Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features. Biomedicines. 2023; 11(2). DOI:10.3390/biomedicines11020541.
Iglesias Tejedor M, Diez A, Llorca Bofi V, Nunez P, Castano Diaz C, Bote B, et al. Relation between EEG resting-state power and modulation of P300 task-related activity in theta band in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2022; 116: 110541-110541. DOI:10.1016/j.pnpbp.2022.110541.
Navines R, Oriolo G, Horrillo I, Cavero M, Aouizerate B, Schaefer M, et al. High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers. Int J Neuropsychopharmacol. 2022; 25(6): 468-478. DOI:10.1093/ijnp/pyac016.
Catalan A, Aymerich C, Bilbao A, Pedruzo B, Pérez JL, Aranguren N, et al. Psychosis and Substance Abuse increase the COVID-19 mortality risk. Psychol Med. 2022: 1-9. DOI:10.1017/S0033291722000976.
Almodovar Paya C, Guardiola Ripoll M, Giralt Lopez M, Gallego C, Salgado Pineda P, Miret S, et al. NRN1 Gene as a Potential Marker of Early-Onset Schizophrenia: Evidence from Genetic and Neuroimaging Approaches. Int J Mol Sci. 2022; 23(13). DOI:10.3390/ijms23137456.
Erkizia Santamaria I, Alles Pascual R, Horrillo I, Meana JJ, Ortega JE. Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. Biomed Pharmacother. 2022; 154: 113612-113612. DOI:10.1016/j.biopha.2022.113612.
Martinez Torres S, Bergada Martinez A, Ortega JE, Galera Lopez L, Hervera A, de los Reyes Ramirez L, et al. Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism. Neuropsychopharmacology. 2022; 48(2): 341-350. DOI:10.1038/s41386-022-01436-9.
Saunders JM, Muguruza C, Sierra S, Moreno JL, Callado LF, Meana JJ, et al. Glucocorticoid receptor dysregulation underlies 5-HT2AR-dependent synaptic and behavioral deficits in a mouse neurodevelopmental disorder model. J Biol Chem. 2022; 298(11): 102481-102481. DOI:10.1016/j.jbc.2022.102481.
Blanco Rey M, Castrillo Bodero R, Ali K, Gargiani P, Bertran F, Sheverdyaeva PM, et al. Effect of the valence state on the band magnetocrystalline anisotropy in two-dimensional rare-earth/noble-metal compounds. Phys Rev Res. 2022; 4(1). DOI:10.1103/PhysRevResearch.4.013237.
Costas Insua C, Hermoso Lopez A, Moreno E, Alvaro Blazquez A, Montero C, Martin Gutierrez D, et al. CB1R as a potential therapeutic target in CRBN deficiency-associated mental retardation. FEBS Open Bio. 2022; 12: 202-202
Molina V, Fernandez Linsenbarth I, Queipo Llano M, Jimenez Aparicio MT, Vallecillo Adame C, Aremy Gonzaga A, et al. Real-life outcomes in biotypes of psychotic disorders based on neurocognitive performance. Eur Arch Psych Clin Neurosci. 2022. DOI:10.1007/s00406-022-01518-1.
Casaletto K, Ramos Miguel A, VandeBunte A, Memel M, Buchman A, Bennett D, et al. Late-life physical activity relates to brain tissue synaptic integrity markers in older adults. Alzheimers Dement. 2022; 18(11): 2023-2035. DOI:10.1002/alz.12530.
Ibarra Lecue I, Diez Alarcia R, Uriguen L. Serotonin 2A receptors and cannabinoids. Prog Brain Res. 2021; 259: 135-175. DOI:10.1016/bs.pbr.2021.01.004.
Fernandez Abascal B, Recio Barbero M, Saenz Herrero M, Segarra R. Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. Ther Adv Psychopharm. 2021; 11. DOI:10.1177/2045125321991277.
Soria Gomez E, Pagano Zottola AC, Mariani Y, Desprez T, Barresi M, Bonilla Del Rio I et al. Subcellular specificity of cannabinoid effects in striatonigral circuits. Neuron. 2021; 109(9). DOI:10.1016/j.neuron.2021.03.007.
Muneta Arrate I, Diez Alacia R, Horillo I, Meana JJ. Enhanced coupling of the 5-HT2A receptor with G alpha i1-protein in post-mortem frontal cortex of subjects with schizophrenia. Eur Neuropsychopharmacol. 2021; 44: 4-4. DOI:10.1016/j.euroneuro.2021.01.012.
Odagaki Y, Kinoshita M, Meana JJ, Callado LF, Garcia Sevilla JA. 5-HT2A receptor- and M-1 muscarinic acetylcholine receptor-mediated activation of G alpha(q/11) in postmortem dorsolateral prefrontal cortex of opiate addicts. Pharmacol Rep. 2021; 73(4): 1155-1163. DOI:10.1007/s43440-021-00248-w.
Diez Alarcia R, Odagaki Y, Miranda Azpiazu P, Gabilondo AM, Meana JJ, Muneta Arrate I. Functional approaches to the study of G-protein-coupled receptors in postmortem brain tissue: [35S]GTPgammaS binding assays combined with immunoprecipitation. Pharmacol Rep. 2021; 73(4): 1079-1095. DOI:10.1007/s43440-021-00253-z.
Recio Barbero M, Segarra R, Zabala A, Gonzalez Fraile E, Gonzalez Pinto A, Ballesteros J. Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms. Front Psychiatry. 2021; 12: 631589-631589. DOI:10.3389/fpsyt.2021.631589.
Nunez delMoral A, Brocos Mosquera I, Vialou V, Callado LF, Erdozain AM. Characterization of hevin (SPARCL1) immunoreactivity in postmortem human brain homogenates. Neuroscience. 2021; 467: 91-109. DOI:10.1016/j.neuroscience.2021.05.017.
Diez Alarcia R, Muguruza C, Rivero G, Garcia Bea A, Gomez Vallejo V, Callado LF et al. Opposite alterations of 5-HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile. Transl Psychiatr. 2021; 11(1): 302-302. DOI:10.1038/s41398-021-01430-7.
Segarra R, Recio Barbero M, Saenz Herrero M, Mentxaka O, Cabezas Garduno J, Eguiluz JI et al. Oral and Palmitate Paliperidone Long-Acting Injectable Formulations use in Schizophrenia Spectrum Disorders: a retrospective cohort study from the CRUPEP First Episode Psychosis Intervention Program. Int J Neuropsychopharmacol. 2021; 24(9): 694-702. DOI:10.1093/ijnp/pyab021.
Diez Alarcia R, Odagaki Y, Miranda Azpiazu P, GABILONDO AM, Meana JJ, Muneta Arrate I. Functional approaches to the study of G-protein-coupled receptors in postmortem brain tissue: [S-35]GTP gamma S binding assays combined with immunoprecipitation (Apr, 10.1007/s43440-021-00253-z, 2021). Pharmacol Rep. 2021; 73(4): 1203-1203. DOI:10.1007/s43440-021-00268-6.
MacDowell KS, Munarriz Cuezva E, Meana JJ, Leza JC, Ortega JE. Paliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathways. Front Pharmacol. 2021; 12: 682602-682602. DOI:10.3389/fphar.2021.682602.
Egusquiza I, Munarriz Cuezva E, Segarra R, Gonzalez Maeso J, Callado LF, Meana JJ et al. Characterization of dopamine D-2 receptor coupling to G proteins in postmortem brain of subjects with schizophrenia. Pharmacol Rep. 2021; 73(4): 1136-1146. DOI:10.1007/s43440-021-00305-4.
Brocos Mosquera I, Gabilondo AM, Diez Alarcia R, Muguruza C, Erdozain AM, Meana JJ et al. alpha2A- and alpha2C-adrenoceptor expression and functionality in postmortem prefrontal cortex of schizophrenia subjects. Eur Neuropsychopharmacol. 2021; 52: 3-11. DOI:10.1016/j.euroneuro.2021.05.012.
Nunez delMoral A, Brocos Mosquera I, Vialou V, Callado LF, Erdozain AM. The matricellular protein hevin is overexpressed in alcoholism: a study in postmortem human brain. Eur Neuropsychopharmacol. 2021; 44: 8-8. DOI:10.1016/j.euroneuro.2021.01.017.
Rodriguez Arevalo S, Bagan A, Grinan Ferre C, Vasilopoulou F, Pallas M, Brocos Mosquera I et al. Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease. Eur J Med Chem. 2021; 222: 113540-113540. DOI:10.1016/j.ejmech.2021.113540.
Odagaki Y, Meana JJ. Special issue "role of G-proteins and GPCR-mediated signaling in the pathophysiology and treatment of psychiatric disorders". Pharmacol Rep. 2021; 73(4): 967-969. DOI:10.1007/s43440-021-00313-4.
Lopez Atanes M, Pijoan Zubizarreta JI, Gonzalez Briceno JP, Leones Gil EM, Recio Barbero M, Gonzalez Pinto A et al. Gender-Based Analysis of the Psychological Impact of the COVID-19 Pandemic on Healthcare Workers in Spain. Front Psychiatry. 2021; 12: 692215-692215. DOI:10.3389/fpsyt.2021.692215.
Turuelo M, Acera A, Diez Cirarda M, Fernandez T, Tijero B, Carmona M et al. Visual cognition differences between asymptomatic and symptomatic carriers of Huntington's disease (HD). Mov Disord. 2021; 36: 113-113
Moreno M, Ortiz R, Almodovar Paya C, Guardiola Ripoll M, Callado LF, Fatjo Vilas M et al. NRN1 EXPRESSION IN BRAIN: ANALYSIS IN INDIVIDUALS DIAGNOSED WITH SCHIZOPHRENIA PATIENTS AND HEALTHY SUBJECTS. Eur Neuropsychopharmacol. 2021; 51: 235-236. DOI:10.1016/j.euroneuro.2021.08.248.
Costas Insua C, Moreno E, Maroto IB, Ruiz Calvo A, Bajo Graneras R, Martin Gutierrez D et al. Identification of BiP as a CB1 Receptor-Interacting Protein That Fine-Tunes Cannabinoid Signaling in the Mouse Brain. J Neurosci. 2021; 41(38): 7924-7941. DOI:10.1523/JNEUROSCI.0821-21.2021.
Gonzalez Ortega I, Alberich Mesa S, Echeburua E, Bernardo M, Cabrera B, Amoretti S et al. Social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. Eur Psychiat. 2021; 64: 163-163. DOI:10.1192/j.eurpsy.2021.436.
Recio Barbero M, Santorcuato A, Bacigalupe A, Lopez Atanes M, Fuertes Soriano S, Cabezas Garduno J et al. Gender differences among psychiatric patients attended in a emergency department. Eur Psychiat. 2021; 64: 600-600. DOI:10.1192/j.eurpsy.2021.1600.
Fernandez Linsenbarth I, Planchuelo Gomez A, Beno Sierra RM, Diez A, Arjona A, Perez A et al. Search for schizophrenia and bipolar biotypes using functional network properties. Brain Behav. 2021; 11(12). DOI:10.1002/brb3.2415.
Brocos Mosquera I, Miranda Azpiazu P, Muguruza C, Corzo Monje V, Morentin B, Meana JJ et al. Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment. Transl Psychiatr. 2021; 11(1). DOI:10.1038/s41398-021-01762-4.
Lopez Atanes M, Gonzalez Briceno JP, Abeal Adham A, Fuertes Soriano S, Cabezas Garduno J, Pena Rotella A et al. Liaison Psychiatry During the Peak of the Coronavirus Pandemic: A Description of Referrals and Interventions. Front Psychiatry. 2021; 12. DOI:10.3389/fpsyt.2021.555080.
Cordero Ruiz N, Meana JJ, Muguruza C, Ortega JE. Molecular evaluation of neuroinflammatory signaling in a double-hit mouse model of cognitive deficits of schizophrenia. Eur Neuropsychopharmacol. 2021; 53: 401-402. DOI:10.1016/j.euroneuro.2021.10.515.
DelaCuesta Barrutia J, Penagarikano O, Morentin B, Callado LF, Meana JJ, Erdozain AM et al. Dopamine D2, cannabinoid CB1, metabotropic glutamate mGlu2 and mGlu3 receptor protein expression in the prefrontal cortex of subjects with schizophrenia. Eur Neuropsychopharmacol. 2021; 53: 356-357. DOI:10.1016/j.euroneuro.2021.10.456.
Erkizia Santamaria I, Alles Pascual R, Horrillo I, Meana JJ, Ortega JE. Evaluation of the acute mechanism of action of psilocybin in mice. Eur Neuropsychopharmacol. 2021; 53: 215-216. DOI:10.1016/j.euroneuro.2021.10.282.
Martinez Peula O, Rivero G, Diaz Grijuela E, Munarriz Cuezva E, Erdozain AM, Meana JJ et al. Selective downregulation of cortical mglu2 receptors in the maternal immune activation model of schizophrenia: association with histone posttranslational modifications. Eur Neuropsychopharmacol. 2021; 53: 214-215. DOI:10.1016/j.euroneuro.2021.10.281.
Meana JJ, Muneta Arrate I, Horrillo I, Diez Alarcia R. Increased serotonin 5HT2A receptor constitutive activity on G alpha i1-but not G alpha q/11-proteins in human prefrontal cortex of subjects with schizophrenia. Eur Neuropsychopharmacol. 2021; 53: 447-448. DOI:10.1016/j.euroneuro.2021.10.574.
Munarriz Cuezva E, Cordero Ruiz N, Martinez Peula O, Unzueta Larrinaga P, Meana JJ. Weight and temperature monitoring of pregnant dams in the poly(I:C) maternal immune activation model of schizophrenia. Strain and batch influence. Eur Neuropsychopharmacol. 2021; 53: 616-616. DOI:10.1016/j.euroneuro.2021.10.701.
Muneta Arrate I, Diez Alacia R, Horrillo I, Meana JJ. Evaluation of serotonin 5HT2A receptor functional selectivity and inverse agonist properties of different antipsychotic drugs in human post-mortem brain cortex. Eur Neuropsychopharmacol. 2021; 53: 165-166. DOI:10.1016/j.euroneuro.2021.10.219.
Recio Barbero M, Cabezas Garduno J, Ruiz Irastorza G, Horrillo I, Meana JJ, Gonzalez Melero MI et al. Mood and anxiety disorders in Systemic Lupus Erythematosus: results and insights from the Lupus-Cruces cohort. Eur Neuropsychopharmacol. 2021; 53: 538-539. DOI:10.1016/j.euroneuro.2021.10.805.
Unzueta Larrinaga P, Ibarra Lecue I, Barrena Barbadillo R, Diez Alarcia R, Landabaso MA, Mendibil B et al. Cannabis abuse differently regulates 5-HT2A receptors and Akt protein in platelets of subjects with schizophrenia. Eur Neuropsychopharmacol. 2021; 53: 666-667. DOI:10.1016/j.euroneuro.2021.10.763.
Nunez delMoral A, Bianchi PC, Cruz FC, Vialou V, Callado LF, Erdozain AM. Alcohol chronic administration and relapse alter the expression levels of the protein hevin in the nucleus accumbens in mice. Eur Neuropsychopharmacol. 2021; 53: 185-186. DOI:10.1016/j.euroneuro.2021.10.245.
González Ortega I, González Pinto A, Alberich S, Echeburúa E, Bernardo M, Cabrera B, et al. Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. Psychol Med. 2020; 50(16): 1-9. DOI:10.1017/S0033291719002794.
Odagaki Y, Kinoshita M, Meana JJ, Callado LF, García Sevilla JA. Functional coupling of M 1 muscarinic acetylcholine receptor to Ga q/11 in dorsolateral prefrontal cortex from patients with psychiatric disorders: a postmortem study. Eur Arch Psych Clin Neurosci. 2020; 270(7): 869-880. DOI:10.1007/s00406-019-01088-9.
Muneta Arrate I, Diez Alarcia R, Horrillo I, Meana JJ. Functional selectivity of different serotonin 5-HT2A receptor antagonists in human post-mortem brain cortex. Eur Neuropsychopharmacol. 2020; 31: 11-12. DOI:10.1016/j.euroneuro.2019.12.016.
Ibarra Lecue I, Diez Alarcia R, Morentin B, Meana JJ, Callado LF, Uriguen L. Ribosomal Protein S6 Hypofunction in Postmortem Human Brain Links mTORC1-Dependent Signaling and Schizophrenia. Front Pharmacol. 2020; 11: 344-344. DOI:10.3389/fphar.2020.00344.
Molina V, Lubeiro A, de Luis Garcia R, Gomez Pilar J, Martín Santiago O, Iglesias Tejedor M, et al. Deficits of entropy modulation of the EEG: A biomarker for altered function in schizophrenia and bipolar disorder?. J Psychiatry Neurosci. 2020; 45(3): 190032-190032. DOI:10.1503/jpn.190032.
Martinez Uribe D, Etxeandia Pradera JI, Bobes García J, Morán Barrios J, Ruiz de Gauna P, Sáenz Herrero M, et al. The training of Psychiatry resident: Summary of the discussion table held during the XXII National Congress of Psychiatry. Spain, 2019. Rev Psiquiatr Salud Ment. 2020; 14(1): 74-76. DOI:10.1016/j.rpsm.2020.03.001.
Abas S, Rodriguez Arevalo S, Bagan A, Grinan Ferre C, Vasilopoulou F, Brocos Mosquera I, et al. Bicyclic alpha-Iminophosphonates as High Affinity Imidazoline I-2 Receptor Ligands for Alzheimer's Disease. J Med Chem. 2020; 63(7): 3610-3633. DOI:10.1021/acs.jmedchem.9b02080.
de Salas Quiroga A, Garcia Rincon D, Gomez Dominguez D, Valero M, Simon Sanchez S, Paraiso Luna J, et al. Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure. Neuropsychopharmacology. 2020; 45(5): 877-886. DOI:10.1038/s41386-020-0621-3.
Nunez A, Vialou V, Meana JJ, Callado LF, Erdozain AM. Study of the role of the matricellular protein hevin in major depression. Eur Neuropsychopharmacol. 2020; 31: 8-9. DOI:10.1016/j.euroneuro.2019.12.011.
Muneta Arrate I, Diez Alarcia R, Horrillo I, Meana JJ. Pimavanserin exhibits serotonin 5-HT2A receptor inverse agonism for Galphai1- and neutral antagonism for Galphaq/11-proteins in human brain cortex. Eur Neuropsychopharmacol. 2020; 36: 83-89. DOI:10.1016/j.euroneuro.2020.05.004.
Vidal Domenech F, Riquelme G, Pinacho R, Rodriguez Mias R, Vera A, Monje A, et al. Calcium-binding proteins are altered in the cerebellum in schizophrenia. PLoS One. 2020; 15(7): 230400-230400. DOI:10.1371/journal.pone.0230400.
Lopez Atanes M, Recio Barbero M, Saenz Herrero M. Are Women Still "the Other"? Gendered Mental Health Interventions for Health Care Workers in Spain During COVID-19. Psychol Trauma. 2020; 12: 243-244. DOI:10.1037/tra0000751.
Recio Barbero M, Saenz Herrero M, Segarra R. Deafness and Mental Health: Clinical Challenges During the COVID-19 Pandemic. Psychol Trauma. 2020; 12: 212-213. DOI:10.1037/tra0000729.
Oliveira da Cruz JF, Ioannidou C, Pagano Zottola AC, Muguruza C, Gomez Sotres P, Fernandez M, et al. Sex-dependent pharmacological profiles of the synthetic cannabinoid MMB-Fubinaca. Addict Biol. 2020; 26(3). DOI:10.1111/adb.12940.
Blasco Fontecilla H, Herranz Herrer J, Ponte Lopez T, Gil Benito E, Donoso Navarro E, Hernandez Alvarez E, et al. Serum beta-endorphin levels are associated with addiction to suicidal behavior: A pilot study. Eur Neuropsychopharmacol. 2020; 40: 38-51. DOI:10.1016/j.euroneuro.2020.07.010.
Martinez Peula O, Rivero G, Morentin B, Callado LF, Javier Meana J, Ramos Miguel A. HISTONE H3 AND H4 POST-TRANSLATIONAL REGULATION IN SCHIZOPHRENIA POSTMORTEM BRAIN: EFFECT OF ANTIPSYCHOTIC TREATMENT. Schizophr Bull. 2020; 46: 107-107
Odagaki Y, Kinoshita M, Javier Meana J, Callado LF, Garcia Sevilla JA. Fundamental features of receptor-mediated Galphai/o activation in human prefrontal cortical membranes: A postmortem study. Brain Res. 2020; 1747: 147032-147032. DOI:10.1016/j.brainres.2020.147032.
Sanjuan J, Helga Castro Martinez X, Garcia Marti G, Gonzalez Fernandez J, Sanz Requena R, Maria Haro J et al. FOXP2expression and gray matter density in the male brains of patients with schizophrenia. Brain Imaging Behav. 2021; 15(3): 1403-1411. DOI:10.1007/s11682-020-00339-x.
Morentin B, Suarez Mier MP, Monzo A, Ballesteros J, Molina P, Lucena J. Sports-related sudden cardiac death in Spain. A multicenter, population-based, forensic study of 288 cases. Rev Esp Cardiol (Engl Ed). 2020; 74(3): 225-232. DOI:10.1016/j.rec.2020.05.044.
Valle Leon M, Callado LF, Aso E, Cajiao Manrique MM, Sahlholm K, Lopez Cano M, et al. Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia. Neuropsychopharmacology. 2020; 46(3): 665-672. DOI:10.1038/s41386-020-00872-9.
Odagaki Y, Kinoshita M, Meana JJ, Callado LF, Garcia Sevilla JA. 5-HT2A receptor-mediated G alpha(q/11) activation in psychiatric disorders: A postmortem study. World J Biol Psychiatry. 2020; 22(7): 505-515. DOI:10.1080/15622975.2020.1839967.
Abas S, Rodriguez Arevalo S, Bagan A, Grinan Ferre C, Vasilopoulou F, Brocos Mosquera I, et al. Bicyclic alpha-Iminophosphonates as High Affinity Imidazoline I-2 Receptor Ligands for Alzheimer's Disease (vol 63, pg 3610, 2020). J Med Chem. 2020; 63(18): 10529-10529. DOI:10.1021/acs.jmedchem.0c01324.
Brocos Mosquera I, Gabilondo AM, Meana JJ, Callado LF, Erdozain AM. Spinophilin expression in postmortem prefrontal cortex of schizophrenic subjects: Effects of antipsychotic treatment. Eur Neuropsychopharmacol. 2020; 42: 12-21. DOI:10.1016/j.euroneuro.2020.11.011.
McMullan M, Kelly B, Mihigo HB, Keogh AP, Rodriguez F, Brocos Mosquera I, et al. Di-aryl guanidinium derivatives: Towards improved alpha2-Adrenergic affinity and antagonist activity. Eur J Med Chem. 2020; 209: 112947-112947. DOI:10.1016/j.ejmech.2020.112947.
Prischich D, Gomila AMJ, Milla Navarro S, Sanguesa G, Diez Alarcia R, Preda B, et al. Adrenergic modulation with photochromic ligands. Angew Chem Int Ed Engl. 2020; 60(7): 3625-3631. DOI:10.1002/anie.202010553.
Recio Barbero M, Cabezas Garduno J, Zabala A, Ferreiro M, Ugarte A, Ruiz Irastorza G, et al. Neuropsychiatric symptoms in patients with systemic lupus erythematosus: prevalence and its impact on quality of life. Eur Neuropsychopharmacol. 2020; 40: 211-212. DOI:10.1016/j.euroneuro.2020.09.276.
Muguruza C, Cordero N, Meana JJ, Ortega JE. A novel double-hit animal model of schizophrenia: behavioural assessment in male and female mice. Eur Neuropsychopharmacol. 2020; 40: 53-54. DOI:10.1016/j.euroneuro.2020.09.074.
Recio Barbero M, Cabezas Garduno J, Fuertes Soriano S, Lopez Atanes M, Gonzalez Briceno JP, Mentxaka O, et al. Paliperidone palmitate long-acting formulations in recent-onset psychosis: a retrospective, non-interventional study. Eur Neuropsychopharmacol. 2020; 40: 320-321. DOI:10.1016/j.euroneuro.2020.09.413.
Lopez Atanes M, Recio Barbero M, Fuertes Soriano S, Cabezas Garduno J, Gonzalez Briceno JP, Segarra Echevarria R, et al. Potential cytochrome P450 psychotropic drug interactions in an in-patient psychiatric population. Eur Neuropsychopharmacol. 2020; 40: 276-276. DOI:10.1016/j.euroneuro.2020.09.359.
Brocos Mosquera I, Gabilondo AM, Meana JJ, Erdozain AM, Callado LF. Alteration of G-alpha protein subtypes expression in postmortem prefrontal cortex of subjects with schizophrenia. Eur Neuropsychopharmacol. 2020; 40: 334-335. DOI:10.1016/j.euroneuro.2020.09.431.
Salgueiro M, Segarra R. Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review. Int Clin Psychopharmacol. 2019; 34(2): 51-56. DOI:10.1097/YIC.0000000000000249.
Morentin B, Callado LF. Sudden cardiac death associated to substances of abuse and psychotropic drugs consumed by young people: A population study based on forensic autopsies. Drug Alcohol Depend. 2019; 201: 23-28. DOI:10.1016/j.drugalcdep.2019.03.021.
Arango C, Baeza I, Bernardo M, Canas F, de Dios C, Diaz Marsa M, et al. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Rev Psiquiatr Salud Ment. 2019; 12(2): 92-105. DOI:10.1016/j.rpsm.2018.03.006.
Neus Fullana M, Ferres Coy A, Ortega JE, Ruiz Bronchal E, Paz V, Javier Meana J, et al. Selective Knockdown of TASK3 Potassium Channel in Monoamine Neurons: a New Therapeutic Approach for Depression. Mol Neurobiol. 2019; 56(4): 3038-3052. DOI:10.1007/s12035-018-1288-1.
Erdozain AM, Brocos Mosquera I, Gabilondo AM, Meana JJ, Callado LF. Differential alpha(2A)- and alpha(2C)-adrenoceptor protein expression in presynaptic and postsynaptic density fractions of postmortem human prefrontal cortex. J Psychopharmacol. 2019; 33(2): 244-249. DOI:10.1177/0269881118798612.
Rivero G, Muguruza C, Corzo V, Meana JJ, Callado LF. ADRA2A and ADRA2C gene expression in post-mortem brain is differentially upregulated in subjects with major depressive disorder and schizophrenia. Eur Neuropsychopharmacol. 2019; 29(1): 40-41. DOI:10.1016/j.euroneuro.2018.11.1012.
Muguruza C, Morentin B, Javier Meana J, Alexander SPH, Callado LF. Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia. J Psychopharmacol. 2019; 33(9): 1132-1140. DOI:10.1177/0269881119857205.
Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, Garcia Sevilla JA. 5-HT2A receptor- and M1 muscarinic acetyl-choline receptor-mediated Galpha(q) signalling in patients with psychiatric disorders. Eur Neuropsychopharmacol. 2019; 29(1): 43-44. DOI:10.1016/j.euroneuro.2018.11.1015.
Brocos Mosquera I, Erdozain AM, Meana JJ, Callado LF, Diez Alarcia R. Alterations in alpha 2A-adrenoceptor mediated G-protein signalling in postmortem prefrontal cortex of schizophrenia subjects. Eur Neuropsychopharmacol. 2019; 29(2): 638-639. DOI:10.1016/j.euroneuro.2019.01.011.
Draminsky Petersen H, Morentin B. Assessing the level of credibility of allegations of physical torture. Forensic Sci Int. 2019; 301: 263-270. DOI:10.1016/j.forsciint.2019.05.043.
Grinan Ferre C, Vasilopoulou F, Abas S, Rodriguez Arevalo S, Bagan A, Sureda FX, et al. Behavioral and Cognitive Improvement Induced by Novel Imidazoline I-2 Receptor Ligands in Female SAMP8 Mice. Neurotherapeutics. 2019; 16(2): 416-431. DOI:10.1007/s13311-018-00681-5.
Mongredien R, Erdozain AM, Dumas S, Cutando L, Nunez del Moral A, Puighermanal E, et al. Cartography of hevin-expressing cells in the adult brain reveals prominent expression in astrocytes and parvalbumin neurons. Brain Struct Funct. 2019; 224(3): 1219-1244. DOI:10.1007/s00429-019-01831-x.
Horrillo I, Ortega JE, Diez Alarcia R, Uriguen L, Javier Meana J. Chronic fluoxetine reverses the effects of chronic corticosterone treatment on alpha(2)-adrenoceptors in the rat frontal cortex but not locus coeruleus. Neuropharmacology. 2019; 158: 107731-107731. DOI:10.1016/j.neuropharm.2019.107731.
Callado LF, Ibarra Lecue I, Diez Alarcia R, Meana JJ, Uriguen L. Decreased ribosomal protein S6 phosphorylation in post-mortem prefrontal cortex of subjects with schizophrenia: Effects of antipsychotic treatment. Eur Neuropsychopharmacol. 2019; 29(1): 321-321. DOI:10.1016/j.euroneuro.2018.11.495.
Brocos Mosquera I, Rivero G, Morentin B, Meana JJ, Callado LF. Histone acetylation and methylation at ADRA2A gene promoter in postmortem prefrontal cortex of subjects with schizophrenia. Eur Neuropsychopharmacol. 2019; 29(1): 325-326. DOI:10.1016/j.euroneuro.2018.11.501.
Diez Alarcia R, Muguruza C, Rivero G, Garcia Bea A, Callado LF, Martin A, et al. Human cerebral 5-HT2A receptor labelling with [18F]altanserin, [3H]LSD, and [3H]M100907. Relevance of radiotracer intrinsic activity. Eur Neuropsychopharmacol. 2019; 29(1): 324-324. DOI:10.1016/j.euroneuro.2018.11.499.
Prades R, Munarriz Cuezva E, Uriguen L, Meana JJ, Tarrago T. IPR-166: a potent and selective prolyl oligopeptidase inhibitor ameliorates cognitive symptoms associated to schizophrenia after oral administration. Eur Neuropsychopharmacol. 2019; 29(1): 244-244. DOI:10.1016/j.euroneuro.2018.11.390.
Odagaki Y, Kinoshita M, Ota T, Javier Meana J, Callado LF, Garcia Sevilla JA. Optimization and pharmacological characterization of receptor-mediated G(i/o) activation in postmortem human prefrontal cortex. Basic Clin Pharmacol Toxicol. 2019; 124(6): 649-659. DOI:10.1111/bcpt.13183.
Muguruza C, Palomo Ruiz JL, Morentin B, Callado LF, Gonzalez Maeso J, Meana JJ. Serotonin 2A receptors in the postmortem prefrontal cortex of suicide victims: the relevance of controlling confounding variables. Eur Neuropsychopharmacol. 2019; 29(1): 325-325. DOI:10.1016/j.euroneuro.2018.11.500.
Morentin Campillo B, Molina Aguilar P, Monzo Blasco A, Laborda Galvez JL, Arrieta Perez J, Sancho Jimenez J, et al. Sudden Death Due to Thoracic Aortic Dissection in Young People: A Multicenter Forensic Study. Rev Esp Cardiol. 2019; 72(7): 553-561. DOI:10.1016/j.rec.2018.07.008.
Diez Alarcia R, Yanez Perez V, Muneta Arrate I, Arrasate S, Lete E, Meana JJ, et al. Big Data Challenges Targeting Proteins in GPCR Signaling Pathways; Combining PTML-ChEMBL Models and [(35) S]GTP gamma S Binding Assays. ACS Chem Neurosci. 2019; 10(11): 4476-4491. DOI:10.1021/acschemneuro.9b00302.
Garcia Bea A, Miranda Azpiazu P, Muguruza C, Marmolejo Artesero S, Diez Alarcia R, Gabilondo AM, et al. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via G(alpha i1)-proteins. Eur Neuropsychopharmacol. 2019; 29(12): 1453-1463. DOI:10.1016/j.euroneuro.2019.10.013.
Horrillo I, Reyes BA, Lhamo T, Meana JJ, Van Bockstaele EJ. Serotonergic 5-HT2A receptors are expressed in noradrenergic locus coeruleus neurons in rats. Eur Neuropsychopharmacol. 2019; 29(6): 372-373. DOI:10.1016/j.euroneuro.2019.09.534.
Muneta Arrate I, Diez Alarcia R, Horrillo I, Meana JJ. Pimavanserin behaves as serotonin 5-HT2A receptor inverse agonist selective for g alpha i/o but not g alpha q/11 proteins in human prefrontal cortex. Eur Neuropsychopharmacol. 2019; 29(6): 78-79. DOI:10.1016/j.euroneuro.2019.09.145.
Alberich S, Fernández Sevillano J, González Ortega I, Usall J, Sáenz M, González Fraile E, et al. A systematic review of sex-based differences in effectiveness and adverse effects of clozapine. Psychiatry Res. 2019; 280: 112506-112506. DOI:10.1016/j.psychres.2019.112506.
Recio Barbero M, Fuertes Soriano S, Cabezas Garduño J, López Atanes M, Peña Rotella A, Sáenz Herrero M. Delayed Diagnosis of an Eating Disorder in a Male Patient With Superior Mesenteric Artery Syndrome: Results From a Case Study. Front Psychiatry. 2019; 10: 731-731. DOI:10.3389/fpsyt.2019.00731.
Ruso Julve F, Pombero A, Pilar Cuéllar F, García Díaz N, Garcia Lopez R, Juncal Ruiz M, et al. Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics. Transl Psychiatr. 2019; 9(1): 306-306. DOI:10.1038/s41398-019-0647-7.
Recio Barbero M, Zabala A, Segarra R, Santos B, Ballesteros FJ. Cognitive enhancers in schizophrenia: A meta-analysis of Alpha-7 nicotinic acetylcholine receptor agonists for cognitive deficits and negative symptoms. Eur Neuropsychopharmacol. 2019; 29(6): 465-466. DOI:10.1016/j.euroneuro.2019.09.657.
Brocos Mosquera I, del Moral AN, Morentin B, Meana JJ, Callado LF, Erdozain AM. Characterisation of spinophilin immunoreactivity in postmortem human brain homogenates. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018; 81: 236-242. DOI:10.1016/j.pnpbp.2017.09.019.
Ibarra Lecue I, Pilar Cuellar F, Muguruza C, Florensa Zanuy E, Diaz A, Uriguen L, et al. The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochem Pharmacol. 2018; 157: 97-107. DOI:10.1016/j.bcp.2018.07.009.
Zabala A, Salgueiro M, Saez Atxukarro O, Ballesteros J, Ruiz Irastorza G, Segarra R. Cognitive Impairment in Patients With Neuropsychiatric and Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis. J Int Neuropsychol Soc. 2018; 24(6): 629-639. DOI:10.1017/S1355617718000073.
Molero P, Ramos Quiroga JA, Martin Santos R, Calvo Sanchez E, Gutierrez Rojas L, Meana JJ. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. CNS Drugs. 2018; 32(5): 411-420. DOI:10.1007/s40263-018-0519-3.
Ordonez Carrasco JL, Salgueiro M, Sayans Jimenez P, Blanc Molina A, Garcia Leiva JM, Calandre EP, et al. Psychometric properties of the Spanish version of the 12-item Interpersonal Needs Questionnaire in fibromyalgia syndrome patients. An Psicol. 2018; 34(2): 274-282. DOI:10.6018/analesps.34.2.293101.
Perez Palomar B, Mollinedo Gajate I, Berrocoso E, Meana JJ, Ortega JE. Serotonin 5-HT3 receptor antagonism potentiates the antidepressant activity of citalopram. Neuropharmacology. 2018; 133: 491-502. DOI:10.1016/j.neuropharm.2018.02.020.
Ibarra Lecue I, Mollinedo Gajate I, Meana JJ, Callado LF, Diez Alarcia R, Uriguen L. Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway. Neuropsychopharmacology. 2018; 43(10): 2028-2035. DOI:10.1038/s41386-018-0076-y.
Cordero N, Muguruza C, Perez Palomar B, Munarriz Cuezva E, Meana JJ, Ortega JE. BEHAVIOURAL EVALUATION OF A TRANSLATIONAL ANIMAL MODEL OF SCHIZOPHRENIA. Basic Clin Pharmacol Toxicol. 2018; 123: 59-59
Muneta Arrate I, Horrillo I, Perez Palomar B, Martinez Alberdi L, Ortega JE, Meana JJ. EVALUATION OF LONG-TERM DESIPRAMINE ADMINISTRATION ON alpha(2)-ADRENOCEPTORS REGULATING NORADRENALINE AND SEROTONIN RELEASE IN RAT FRONTAL CORTEX. Basic Clin Pharmacol Toxicol. 2018; 123: 59-59
Rivero G, Brocos Mosquera I, Meana JJ, Callado LF. ADRA2A GENE EXPRESSION AND EPIGENETIC REGULATION IN POSTMORTEM PREFRONTAL CORTEX OF SUBJECTS WITH SCHIZOPHRENIA. Basic Clin Pharmacol Toxicol. 2018; 123: 62-63
Martin Hernandez D, Caso JR, Meana JJ, Callado LF, Madrigal JLM, Garcia Bueno B, et al. Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: effect of antidepressants. J Neuroinflamm. 2018; 15. DOI:10.1186/s12974-018-1294-2.
Lafuente Castro CP, Ordonez Carrasco JL, Garcia Leiva JM, Salgueiro Macho M, Calandre EP. Perceived burdensomeness, thwarted belongingness and suicidal ideation in patients with fibromyalgia and healthy subjects: a cross-sectional study. Rheumatol Int. 2018; 38(8): 1479-1486. DOI:10.1007/s00296-018-4067-4.
Herrero MS. Gender violence and mental health: a gap between clinical assistance and research. Actas Esp Psiquiatr. 2018; 46(1): 31-32
Lopez Cardona AP, Ibarra Lecue I, Laguna Barraza R, Perez Cerezales S, Uriguen L, Agirregoitia N, et al. Effect of chronic THC administration in the reproductive organs of male mice, spermatozoa and in vitro fertilization. Biochem Pharmacol. 2018; 157: 294-303. DOI:10.1016/j.bcp.2018.07.045.
Pallas M, Grinan Ferre C, Abas S, Rodriguez Arevalo S, Bagan A, Vasilopoulou F, et al. NOVEL IMIDAZOLINE I2 RECEPTOR LIGANDS FOR COGNITIVE DECLINE TREATMENT. Basic Clin Pharmacol Toxicol. 2018; 123: 54-54
Callado LF, Ibarra Lecue I, Luque Fernandez V, Meana JJ, Diez Alarcia R, Uriguen L. EFFECTS OF CHRONIC ANTIPSYCHOTICS ADMINISTRATION ON AKT-DEPENDENT SIGNALLING PATHWAYS IN RAT BRAIN CORTEX. Basic Clin Pharmacol Toxicol. 2018; 123: 58-58
Brocos Mosquera I, Gabilondo AM, Meana JJ, Callado LF, Erdozain AM. SPINOPHILIN EXPRESSION IN POSTMORTEM PREFRONTAL CORTEX OF SUBJECTS WITH SCHIZOPHRENIA: EFFECT OF ANTIPSYCHOTIC TREATMENT. Basic Clin Pharmacol Toxicol. 2018; 123: 59-59
Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, Matsuoka I, et al. Functional coupling between adenosine A(1) receptors and G-proteins in rat and postmortem human brain membranes determined with conventional guanosine-5 '-O-(3-[S-35]thio)triphosphate ([S-35]GTP gamma S) binding or [S-35]GTP gamma S/immunoprecipitation assay. Purinergic Signal. 2018; 14(2): 177-190. DOI:10.1007/s11302-018-9603-x.
MacDowell KS, Munarriz Cuezva E, Caso JR, Madrigal JL, Zabala A, Meana JJ, et al. Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia. Neuropharmacology. 2017; 116: 196-207. DOI:10.1016/j.neuropharm.2016.12.025.
Fernandez Pastor B, Ortega JE, Grandoso L, Castro E, Ugedo L, Pazos A, et al. Chronic citalopram administration desensitizes prefrontal cortex but not somatodendritic alpha(2)-adrenoceptors in rat brain. Neuropharmacology. 2017; 114: 114-122. DOI:10.1016/j.neuropharm.2016.11.025.
Prades R, Munarriz Cuezva E, Urigüen L, Gil Pisa I, Gómez L, Mendieta L, et al. The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia. Eur Neuropsychopharmacol. 2017; 27(2): 180-191. DOI:10.1016/j.euroneuro.2016.11.016.
Zabala A, Bustillo M, Querejeta I, Alonso M, Mentxaka O, González Pinto A, et al. A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients. J Clin Psychopharmacol. 2017; 37(5): 569-577. DOI:10.1097/JCP.0000000000000770.
Ibi D, Revenga MD, Kezunovic N, Muguruza C, Saunders JM, Gaitonde SA, et al. Antipsychotic-induced Hdac2 transcription via NF-kappa B leads to synaptic and cognitive side effects. Nat Neurosci. 2017; 20(9): 1247-1247. DOI:10.1038/nn.4616.
Perez Palomar B, Mollinedo Gajate I, Meana JJ, Ortega JE. SEROTONIN 5-HT3 RECEPTOR ANTAGONISM POTENTIATES THE ANTIDEPRESSANT ACTIVITY OF CITALOPRAM. Basic Clin Pharmacol Toxicol. 2017; 121: 40-40
Diaz Gutierrez MJ, Martinez Cengotitabengoa M, de Adana ES, Cano AI, Martinez Cengotitabengoa MT, Besga A, et al. Relationship between the use of benzodiazepines and falls in older adults: A systematic review. Maturitas. 2017; 101: 17-22. DOI:10.1016/j.maturitas.2017.04.002.
Mas S, Gasso P, Torra M, Bioque M, Lobo A, Gonzalez Pinto A, et al. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. Eur Neuropsychopharmacol. 2017; 27(7): 647-656. DOI:10.1016/j.euroneuro.2017.03.012.
Gonzalez Pinto A, Martinez Cengotitabengoa M, Lopez P, Perez P, Saenz M, Zorrilla I. Treatment of bipolar disorder: should we treat men and women differently?. Bipolar Disord. 2017; 19: 146-146
Flood A, Trujillo C, Sanchez Sanz G, Kelly B, Muguruza C, Callado LF, et al. Thiophene/thiazole-benzene replacement on guanidine derivatives targeting alpha(2)-Adrenoceptors. Eur J Med Chem. 2017; 138: 38-50. DOI:10.1016/j.ejmech.2017.06.008.
Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, Garcia Sevilla JA. Functional activation of G alpha(q) coupled to 5-HT2A receptor and M-1 muscarinic acetylcholine receptor in postmortem human cortical membranes. J Neural Transm. 2017; 124(9): 1123-1133. DOI:10.1007/s00702-017-1749-0.
Grinan Ferre C, Abas S, Vasilopoulou F, Erdozain AM, Keller B, Rodriguez Arevalo S, et al. NEUROPROTECTIVE EFFECT OF NOVEL IMIDAZOLINE I-2 RECEPTOR LIGANDS IN THE SENESCENCE ACCELERATED MOUSE PRONE 8 (SAMP8). Basic Clin Pharmacol Toxicol. 2017; 121: 33-33
Ibarra Lecue I, Mollinedo Gajate I, Meana JJ, Callado LF, Diez Alarcia R, Uriguen L. CHRONIC Delta(9)-THC ADMINISTRATION LEADS TO FUNCTIONAL 5HT2A RECEPTORS SUPERSENSITIVITY MEDIATED BY INHIBITORY GI/O PROTEINS IN MOUSE BRAIN CORTEX. Basic Clin Pharmacol Toxicol. 2017; 121: 33-33
Brocos Mosquera I, Gabilondo AM, Meana JJ, Erdozain AM, Callado LF. alpha(2A)- AND alpha(2C)-ADRENOCEPTOR SUBTYPES EXPRESSION IN POSTMORTEM PREFRONTAL CORTEX OF SUBJECTS WITH SCHIZOPHRENIA. Basic Clin Pharmacol Toxicol. 2017; 121: 43-44
Abas S, Erdozain AM, Keller B, Rodriguez Arevalo S, Callado LF, Garcia Sevilla JA, et al. Neuroprotective Effects of a Structurally New Family of High Affinity Imidazoline l(2) Receptor Ligands. ACS Chem Neurosci. 2017; 8(4): 737-742. DOI:10.1021/acschemneuro.6b00426.
Meana JJ, Mollinedo Gajate I. Biomarkers in Psychiatry: Between myth and clinical reality. Rev Psiquiatr Salud Ment. 2017; 10(4): 183-184. DOI:10.1016/j.rpsm.2017.04.003.
Rodriguez Munoz M, Sanchez Blazquez P, Callado LF, Meana JJ, Garzon Nino J. Schizophrenia and depression, two poles of endocannabinoid system deregulation. Transl Psychiatr. 2017; 7(12): 1291-1291. DOI:10.1038/s41398-017-0029-y.
Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callodo LF, Garcia Sevilla JA. Functional activation of Gi/o proteins coupled to multiple neurotransmitter receptors in postmortem human prefrontal cortical membranes. Eur Neuropsychopharmacol. 2017; 27(4): 652-652. DOI:10.1016/S0924-977X(17)31221-X.
Callado LF. ROLE OF SEROTONIN 5-HT3 RECEPTORS IN THE TREATMENT OF DEPRESSIVE DISORDERS. Basic Clin Pharmacol Toxicol. 2017; 121: 21-21
Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, Gonzáles Pinto A, et al. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. Int J Neuropsychopharmacol. 2016; 19(4). DOI:10.1093/ijnp/pyv121.
Mezquida G, Penadés R, Cabrera B, Savulich G, Lobo A, González Pinto A, et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders. Eur Psychiat. 2016; 38: 61-68. DOI:10.1016/j.eurpsy.2016.04.011.
Mas S, Gassó P, Lafuente A, Bioque M, Lobo A, Gonzàlez Pinto A, et al. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. Pharmacogenomics J. 2016; 16(5): 439-445. DOI:10.1038/tpj.2016.44.
Rivero G, Martin Guerrero I, de Prado E, Gabilondo AM, Callado LF, Garcia Sevilla JA, et al. Alpha2C-adrenoceptor Del322-325 polymorphism and risk of psychiatric disorders: significant association with opiate abuse and dependence. World J Biol Psychiatry. 2016; 17(4): 308-315. DOI:10.3109/15622975.2016.1142608.
Garcia Bueno B, Gasso P, MacDowell KS, Callado LF, Mas S, Bernardo M, et al. Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. J Psychiatry Neurosci. 2016; 41(3): 46-55. DOI:10.1503/jpn.150195.
Moreno JL, Miranda Azpiazu P, Garcia Bea A, Younkin J, Cui M, Kozlenkov A, et al. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia. Sci Signal. 2016; 9(410). DOI:10.1126/scisignal.aab0467.
Horrillo I, Ortega JE, Diez Alarcia R, Uriguen L, Javier Meana J. Effect of subchronic corticosterone administration on alpha(2)-adrenoceptor functionality in rat brain: an in vivo and in vitro study. Psychopharmacology. 2016; 233(23-24): 3861-3867. DOI:10.1007/s00213-016-4418-3.
Pinacho R, Villalmanzo N, Javier Meana J, Ferrer I, Berengueras A, Haro JM, et al. Altered CSNK1E, FABP4 and NEFH protein levels in the dorsolateral prefrontal cortex in schizophrenia. Schizophr Res. 2016; 177(1-3): 88-97. DOI:10.1016/j.schres.2016.04.050.
McMullan M, Garcia Bea A, Miranda Azpiazu P, Callado LF, Rozas I. Substituted conformationally restricted guanidine derivatives: Probing the alpha(2)-adrenoceptors' binding pocket. Eur J Med Chem. 2016; 123: 48-57. DOI:10.1016/j.ejmech.2016.07.011.
Diez Alarcia R, Ibarra Lecue I, Lopez Cardona AP, Meana J, Gutierrez Adan A, Callado LF, et al. Biased Agonism of Three Different Cannabinoid Receptor Agonists in Mouse Brain Cortex. Front Pharmacol. 2016; 7. DOI:10.3389/fphar.2016.00415.
García Bueno B, Gassó P, MacDowell KS, Callado LF, Mas S, Bernardo M, et al. Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. J Psychiatry Neurosci. 2016; 41(3). DOI:10.1503/jpn.150195.
Muguruza C, Javier Meana J, Callado LF. Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. Front Pharmacol. 2016; 7. DOI:10.3389/fphar.2016.00130.
Arostegui S, Horrillo I, Sanz Arzuaga C, Intxauspe L, Del Rio D, Ballesteros J, et al. Biochemical parameters associated with neuroinflammation in depressed patients: relationship with clinical intensity. Eur Neuropsychopharmacol. 2016; 26(2): 208-208. DOI:10.1016/S0924-977X(16)31055-0.
Erdozain AM, Rubio M, Valdizan EM, Pazos A, Meana JJ, Fernández Ruiz J, et al. The endocannabinoid system is altered in the post-mortem prefrontal cortex of alcoholic subjects. Addict Biol. 2015; 20(4): 773-783. DOI:10.1111/adb.12160.
Rivero G, Gabilondo AM, Garcia Sevilla JA, La Harpe R, Morentin B, Javier Meana J. Up-regulated 14-3-3 beta and 14-3-3 zeta proteins in prefrontal cortex of subjects with schizophrenia: effect of psychotropic treatment. Schizophr Res. 2015; 161(2-3): 446-451. DOI:10.1016/j.schres.2014.12.014.
Bustillo M, Segarra R, Querejeta I, Gonzalez Pinto A, Mentxaka O, Carton J, et al. Is therapeutic drug monitoring of olanzapine a useful clinical tool in first-episode psychosis patients?. Eur Neuropsychopharmacol. 2015; 25(1): 63-64
Agirregoitia E, Ibarra Lecue I, Totorikaguena L, Mendoza R, Exposito A, Matorras R, et al. Dynamics of expression and localization of the cannabinoid system in granulosa cells during oocyte nuclear maturation. Fertil Steril. 2015; 104(3): 753-760. DOI:10.1016/j.fertnstert.2015.06.013.
Bustillo M, Querejeta I, Segarra R, Gonzalez Pinto A, Alonso M, Mentxaka O, et al. Plasma levels of second generation antipsychotics as indicators of clinical response and severity of side-effects in first-episode psychosis patients. Eur Neuropsychopharmacol. 2015; 25(2): 513-514. DOI:10.1016/S0924-977X(15)30707-0.
Erdozain AM, Rubio M, Javier Meana J, Fernandez Ruiz J, Callado LF. Altered CB1 receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects. J Psychopharmacol. 2015; 29(11): 1137-1145. DOI:10.1177/0269881115599388.
Gilabert Juan J, Rosa Saez A, Lopez Campos G, Sebastia Ortega N, Gonzalez Martinez R, Costa J, et al. Semaphorin and plexin gene expression is altered in the prefrontal cortex of schizophrenia patients with and without auditory hallucinations. Psychiatry Res. 2015; 229(3): 850-857. DOI:10.1016/j.psychres.2015.07.074.
Mollinedo Gajate I, Gonzalez Maeso J, Meana J. Functional interaction between serotonin 2A and metabotropic glutamate 2 receptors in the regulation of dopamine release in mouse prefrontal cortex. Eur Neuropsychopharmacol. 2015; 25(2): 261-262. DOI:10.1016/S0924-977X(15)30300-X.
Mollinedo Gajate I, Gonzalez Maeso J, Meana JJ. Involvement of serotonin 2A-metabotropic glutamate 2 receptor heterocomplex in catecholamine release in mouse prefrontal cortex. Eur Neuropsychopharmacol. 2015; 25(1): 33-34
Gil Pisa I, Mollinedo Gajate I, Marmolejo S, Meana JJ, Gonzalez Maeso J. FUNCTIONAL ACTIVITY OF THE SEROTONIN 5HT2A/MGLU2 RECEPTORS HETEROCOMPLEX IN MOUSE BRAIN. Basic Clin Pharmacol Toxicol. 2015; 117(2, SI): 44-44
Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, Garcia Sevilla JA. Adenosine A(1) receptors are selectively coupled to G alpha(i-3) in postmortem human brain cortex: Guanosine-5 '-O-(3-[S-35]thio)triphosphate ([S-35]GTP gamma S) binding/immunoprecipitation study. Eur J Pharmacol. 2015; 764: 592-598. DOI:10.1016/j.ejphar.2015.07.049.
Pinacho R, Saia G, Javier Meana J, Gill G, Ramos B. Transcription factor SP4 phosphorylation is altered in the postmortem cerebellum of bipolar disorder and schizophrenia subjects. Eur Neuropsychopharmacol. 2015; 25(10): 1650-1660. DOI:10.1016/j.euroneuro.2015.05.006.
Munarriz Cuezva E, Prades R, Urigueen L, Royo S, Giralt E, Tarrago T, et al. The prolyl oligopeptidase inhibitor IPR19 improves cognitive deficits in schizophrenia-like mouse models. Eur Neuropsychopharmacol. 2015; 25(2): 479-479. DOI:10.1016/S0924-977X(15)30651-9.
Prades R, Munarriza Cuezva E, Urigueen L, Royo S, Giralt E, Meana J, et al. Selective prolyl oligopeptidase inhibition by IPR19 as a new pharmacological treatment of the cognitive impairment associated with schizophrenia. Eur Neuropsychopharmacol. 2015; 25(2): 479-480. DOI:10.1016/S0924-977X(15)30652-0.
Kelly B, McMullan M, Muguruza C, Ortega JE, Meana JJ, Callado LF, et al. alpha(2)-Adrenoceptor Antagonists: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of Pyridinoguanidine, Pyridino-2-aminoimidazoline and Their Derivatives. J Med Chem. 2015; 58(2): 963-977. DOI:10.1021/jm501635e.
Arteaga O, Revuelta M, Urigueen L, Alvarez A, Montalvo H, Hilario E. Pretreatment with Resveratrol Prevents Neuronal Injury and Cognitive Deficits Induced by Perinatal Hypoxia-Ischemia in Rats. PLoS One. 2015; 10(11). DOI:10.1371/journal.pone.0142424.
Javier Meana J, Callado LF, Morentin B. Do post-mortem brain studies provide useful information for Psychiatry?. Rev Psiquiatr Salud Ment. 2014; 7(3): 101-103. DOI:10.1016/j.rpsm.2014.05.001.
Rivero G, Gabilondo AM, García Sevilla JA, La Harpe R, Callado LF, Meana JJ. Increased alpha(2)- and beta(1)-adrenoceptor densities in postmortem brain of subjects with depression: Differential effect of antidepressant treatment. J Affect Disord. 2014; 167: 343-350. DOI:10.1016/j.jad.2014.06.016.
Gil Pisa I, Cebrián C, Ortega JE, Meana JJ, Sulzer D. Cytokine pathway disruption in a mouse model of schizophrenia induced by Munc18-1a overexpression in the brain. J Neuroinflamm. 2014; 11: 128-128. DOI:10.1186/1742-2094-11-128.
García Fuster MJ, Díez Alarcia R, Ferrer Alcón M, La Harpe R, Meana JJ, García Sevilla JA. FADD ADAPTOR AND PEA-15/ERK1/2 PARTNERS IN MAJOR DEPRESSION AND SCHIZOPHRENIA POSTMORTEM BRAINS: BASAL CONTENTS AND EFFECTS OF PSYCHOTROPIC TREATMENTS. Neuroscience. 2014; 277: 541-551. DOI:10.1016/j.neuroscience.2014.07.027.
Muguruza C, Miranda Azpiazu P, Díez Alarcia R, Morentin B, González Maeso J, Callado LF, et al. Evaluation of 5-HT2A and mGlu(2/3) receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment. Neuropharmacology. 2014; 86: 311-318. DOI:10.1016/j.neuropharm.2014.08.009.
Erdozain AM, Callado LF. Neurobiological alterations in alcohol addiction: a review. Adicciones. 2014; 26(4): 360-370. DOI:10.20882/adicciones.40.
O'Donovan DH, Muguruza C, Callado LF, Rozas I. Guanidine-based alpha(2)-adrenoceptor ligands: Towards selective antagonist activity. Eur J Med Chem. 2014; 82: 242-254. DOI:10.1016/j.ejmech.2014.05.057.
Morentin B, Ballesteros J, Callado LF, Javier Meana J. Recent cocaine use is a significant risk factor for sudden cardiovascular death in 15-49-year-old subjects: a forensic case-control study. Addiction. 2014; 109(12): 2071-2078. DOI:10.1111/add.12691.
Fernandez C, Callado LF, Giron R, Sanchez E, Erdozain AM, Antonio Lopez Moreno J, et al. Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Des Dev Ther. 2014; 8: 263-277. DOI:10.2147/DDDT.S55045.
Erdozain AM, Morentin B, Bedford LYNN, King E, Tooth D, Brewer C, et al. Alcohol-Related Brain Damage in Humans. PLoS One. 2014; 9(4). DOI:10.1371/journal.pone.0093586.
Gabilondo AM. EVALUATION EXPERIENCE IN RESEARCH PROJECTS. Basic Clin Pharmacol Toxicol. 2014; 115(2, SI): 3-4
Bustillo M, Alonso M, Gonzalez Pinto A, Segarra R, Zabala A, Roman S, et al. Plasma levels of risperidone in relation to dose, clinical improvement and side-effects in first-episode psychosis. Eur Neuropsychopharmacol. 2014; 24(2): 505-506. DOI:10.1016/S0924-977X(14)70809-0.
Ballesteros J, Guillen V, Zabala A, Santos B, Rueda JR, Sola I. Clinical outcomes in schizophrenia treated with donepezil in combination with antipsychotics. Value Health 2013;16:542. FI: 2,191(Q1). ( Meeting Abstract)
Fernández-Pastor B, Ortega JE, Meana JJ. Involvement of serotonin 5-HT3 receptors in the modulation of noradrenergic transmission by serotonin reuptake inhibitors: a microdialysis study in rat brain. Psychopharmacology. 2013;229:331-44. FI: 4,061(Q1)
Ormaza M, Fernandez L, Lafuente S, Corso M, Schiller F, Xu B, et al. LaAu2 and CeAu2 surface intermetallic compounds grown by high-temperature deposition on Au(111). Phys Rev B. 2013;88: -0. FI: 3,767(Q1)
Meana JJ. Agonist signal trafficking at serotonin 5-ht2a receptor in human brain: implications for schizophrenia and antipsychotic treatment. Basic Clin Pharmacol Toxicol. 2013;113:6. FI: 2,124(Q3). ( Meeting Abstract)
Meana JJ, Fernandez-Pastor B, Ortega JE, Grandoso L, Castro E, Ugedo L, et al. Chronic citalopram administration desensitizes prefrontal cortex but not somatodendritic a2-adrenoceptors in rat brain. Basic Clin Pharmacol Toxicol. 2013;113:17. FI: 2,124(Q3). ( Meeting Abstract)
Meana JJ, Miranda-Azpiazu P, Muguruza C, Diez-Alarcia R, Callado LF, Gonzalez-Maeso J. Different pharmacological properties of ketanserin and altanserin on serotonin 5-ht2a receptors in postmortem human brain: interest for schizophrenia studies. Basic Clin Pharmacol Toxicol. 2013;113:17-8. FI: 2,124(Q3). ( Meeting Abstract).
Muguruza C, Moreno JL, Umali A, Callado LF, Meana JJ, González-Maeso J. Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur Neuropsychopharmacol. 2013;23:852-64. FI: 4,595(Q1)
Muguruza C, Lehtonen M, Aaltonen N, Morentin B, Meana JJ, Callado LF. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophr Res. 2013;148:145-50. FI: 4,590(Q1)
Pinacho R, Villalmanzo N, Roca M, Iniesta R, Monje A, Haro JM, et al. Analysis of Sp transcription factors in the postmortem brain of chronic schizophrenia: A pilot study of relationship to negative symptoms. J Psychiatr Res. 2013;47:926-34. FI: 4,066(Q1)
Ortega JE, Gonzalez-Lira V, Horrillo I, Herrera-Marschitz M, Callado LF, Meana JJ. Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain. Eur J Pharmacol. 2013;709:13-9. FI: 2,592(Q2)
Ramos-Miguel A, Meana JJ, García-Sevilla JA. Cyclin-dependent kinase-5 and p35/p25 activators in schizophrenia and major depression prefrontal cortex: basal contents and effects of psychotropic medications. Int J Neuropsychopharmacol. 2013;16:683-9. FI: 5,641(Q1)
Ojeda N, Peña J, Bengoetxea E, García A, Sánchez P, Elizagárate E, et al. Evidence of the effectiveness of cognitive rehabilitation in psychosis and schizophrenia with the REHACOP programme Reply. Rev Neurol. 2013;56:400. FI: 1,179(Q4)
Rivero G, Gabilondo AM, García-Sevilla JA, Callado LF, La Harpe R, Morentin B, et al. Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment. Psychopharmacology. 2013;226:177-88. FI: 4,061(Q1)
Fernández-Fernández C, Decara J, Bermúdez-Silva FJ, Sánchez E, Morales P, Gómez-Cañas M, et al. Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties. Arch Pharm. 2013;346:171-9. FI: 1,540(Q2)
Muguruza C, Rodríguez F, Rozas I, Meana JJ, Urigüen L, Callado LF. Antidepressant-like properties of three new alpha 2-adrenoceptor antagonists. Neuropharmacology. 2013;65:13-9. FI: 4,114(Q1)
Urigüen L, Gil-Pisa I, Munarriz-Cuezva E, Berrocoso E, Pascau J, Soto-Montenegro ML, et al. Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia. Transl Psychiatr. 2013;3:e221 FI: 0,000(Q0)
Alba-Delgado C, Llorca-Torralba M, Horrillo I, Ortega JE, Mico JA, Sánchez-Blázquez P, et al. Chronic Pain Leads to Concomitant Noradrenergic Impairment and Mood Disorders. Biol Psychiatry. 2013;73:54-62. FI: 9,247(Q1)
Tesis del grupo
Autor/a: Rocío Barrena Barbadillo. Título: Menús escolares en el área metropolitana de Bilbao: un análisis de su adecuación nutricional y de su ingesta. Directores/as: Iñaki X Irastorza Terradillos, Elena Rodríguez Álvarez.
Autor/a: Amaia Núñez del Moral. Título: Hevin proteina matrizelularraren parte-hartzea alkoholismoan: postmortem giza garunean eta animalia-erreduetan burututako lana. Directores/as: Luis Felipe Callado Hernando, Amaia Maite Erdozain Fernández. URL: http://hdl.handle.net/10810/59737.
Autor/a: Natalia Cordero Ruiz. Título: Characterization of a double-hit mouse model of schizophrenia. Focus on inflammatory and epigenetic processes, pharmacological modulation and sex bias. Directores/as: Jorge Ortega Calvo, Carolina Muguruza Millán. URL: http://hdl.handle.net/10810/60053.
Autor/a: María Recio Barbero. Título: Exploración de las alteraciones neuropsiquiátricas cognitivas y neuroinflamatorias el lupus eritematoso sistémico. Directores/as: Rafael Segarra Echevarría, Margarita Sáenz Herrero.
Autor/a: Ines Ibarra Lecue. Título: Molecular mechanisms underlying cannabis abuse and schizophrenia: Focus on 5-HT2A receptors and Akt/mTOR signaling pathway. Directores/as: Dra. Leyre Urigüen Echevarría, Dr. Luis Felipe Callado Hernando. URL: http://hdl.handle.net/10810/50298.
Autor/a: Iria Brocos Mosquera. Título: Estudio de los receptores adrenérgicos α2 y la proteína espinofilina en la corteza prefrontal postmortem de sujetos con esquizofrenia. Directores/as: Dr. Luis Felipe Callado Hernando. URL: http://hdl.handle.net/10810/52814.
Autor/a: Ines Ibarra Lecue. Título: Molecular mechanisms underlying cannabis abuse and schizophrenia: Focus on 5-HT2A receptors and Akt/mTOR signaling pathway. Directores/as: Dra. Leyre Urigüen Echevarría, Dr. Luis Felipe Callado Hernando. URL: http://hdl.handle.net/10810/50298.
Autor/a: Daniel Betancor Pérez. Título: "Estudio sobre identidad de género y". Directores/as: Dr. Juan Francisco Artaloytia Usobiaga , Dr. Rafael Segarra Echebarría.
Autor/a: Ohiane Mentxaka Solozabal. Título: "Predicción de la cesárea mediante una combinación de marcadores ecográficos y de historia clínica". Directores/as: Dr. Rafael Segarra Echebarria , Dr. Jon García Ormaza.
Autor/a: Jon García Ormaza. Título: Suicidio y desempleo: Barakaldo 2003-2014. Director/a: Dr. José Ignacio Eguiluz Uruchurtu, Dr. Rafael Segarra Echevarria. UPV/EHU
Autor/a: Mariana Bustillo Iceta. Título: Utilidad de la monitorización terapéutica de antipsicóticos de segunda generación en la práctica clínica de los primeros episodios psicóticos. Director/a: Dr. Rafael Segarra Echebarría, Dra. Arantzazu Zabala Rabadán. UPV/EHU
Autor/a: Eva Munarriz Cuezva. Título: Caracterización de las proteínas del complejo SNARE en esquizofrenia y su tratamiento. Director/a: Dra. Leyre Urigüen Echeverría, Dr. José Javier Meana Martínez. UPV/EHU